SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
Michael Balmuth Joins SV Life Sciences as Partner - 8 July 2014
Firm Adds Deep Healthcare IT Experience to Healthcare Services Team.
SV Life Sciences ("SVLS"), a leading, international life sciences venture capital firm, today announced the appointment of Michael Balmuth as Partner.
SV Life Sciences Appoints Three New Venture Partners - 2 June, 2014
Firm Adds Significantly to Strength of Biotech Investment Team.
SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Dan Burgess, Dr. Ed Mascioli and Dr. Michael Mendelsohn as new venture partners.